The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Open accessPreprint — published as 10.1038/s41586-020-2639-4 · Paper page
Abstract
In March 2020, the WHO declared a pandemic of coronavirus disease 2019 (COVID-19), due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1 With >8.8 million cases and >450,000 deaths reported globally, a vaccine is urgently needed. We report the available safety, tolerability, and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose escalation study among healthy adults, 18-55 years of age, randomized to receive 2 doses, separated by 21 days, of 10 μg, 30 μg, or 100 μg of BNT162b1, a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD. Local reactions and systemic events were dose-dependent, generally mild to moderate, and transient. RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titers in sera increased with dose level and after a second dose. Geometric mean neutralizing titers reached 1.8-to 2.8-fold that of a panel of COVID-19 convalescent human sera. These results support further evaluation of this mRNA vaccine candidate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The incidence of grade 3 fever of BNT162b1 varied significantly in the same 30 μg group in adults aged 18–55 years, with none (0%) of 12 in the USA,17 one (8%) of 12 in Germany,18 and four (17%) of 24 in China,16 suggesting varying tolerability in different populations.”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [18]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Together with recent reports of the preserved neutralization of SARS-CoV-2 with key S mutations found in the B.1.1.7 and the B.1.351lineage 39,40 , and neutralization of pseudovirus bearing the full set of mutations of B.1.1.7 S 41 , our data indicate broad BNT162b2-elicited immune recognition 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To enable the comparison of vaccine-induced S1-and RBD-binding IgG responses to previously reported data on the BioNTech-Pfizer RNA vaccines for COVID-19, sera were analysed as previously described 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GMTs in subgroups of the donors were as follows: symptomatic infections, 90 (n = 35); asymptomatic infections, 156 (n = 3); hospitalized, 618 (n = 1).”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meanwhile, several studies17, 18, 19 have reported more frequent and severe solicited systemic adverse events following the second vaccination than we found.”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [18]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies17, 18, 19 showed that solicited systemic adverse events were more frequent and more severe at higher doses”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This contrasts with recent reports of mRNA-LNP vaccines against the SARS-CoV-2 virus responsible for the COVID-19 pandemic which had similar rates of reactogenicity and in which reactogenicity noticeably increased after a second dose [17], [18].”
From Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The S glycoprotein mediates host cell attachment and is required for viral entry3; it is the primary vaccine target for many candidate SARS-CoV-2 vaccines.4-7”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those studies showed that solicited systemic adverse events tended to be more frequent and more severe with higher doses and after the second vaccination.”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To enable the comparison of vaccine-induced serum neutralizing titres to those previously reported for BioNTech-Pfizer RNA vaccines for COVID-19, sera were analysed as previously described 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“This descriptive safety profile is similar to that described in a report of two trials of avian influenza mRNA vaccines (influenza A/H10N8 and influenza A/H7N9) that were manufactured by Moderna with the use of an earlier lipid nanoparticle capsule formulation11 and is consistent with an interim report of a phase 1–2 evaluation of a Covid-19 mRNA vaccine encoding the S receptor-binding domain.6”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, the use of high doses of mRNA formulated with lipid nanoparticles (LNPs) resulted in some side effects in the candidates mRNA-1273 and BNT162b1.3,4”
From Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA (2021) · cites this paper as [4]
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [152]
In the citing paper
“an mRNA-based vaccine that encodes the full-length SARS-CoV-2 spike (S) gene1”
From SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses (2021) · cites this paper as [1]
In the citing paper
“However, the vaccine developers eventually decide to proceed with BNT162b2 to phase II/III international clinical trials in view of its milder reactogenicity.277,278,378”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [378]
In the citing paper
“BioNTech and Pfizer collaborated to develop five COVID-19 mRNA vaccine candidates at the beginning of the pandemic, which were based on nucleoside-modified mRNA (BNT162b2, BNT162b1, BNT162b3), non-modified mRNA (BNT162a1) and self-amplifying mRNA (BNT162c2).”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [376]
In the citing paper
“Clinical trial data indicated that both mRNA vaccine candidates induced neutralizing antibodies at a comparable level.”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [378]
In the citing paper
“Till now, all of these candidates have entered clinical trials (Table 5).130,376,377”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [376]
In the citing paper
“8–50-fold higher anti-RBD IgG”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [123]
In the citing paper
“1.9–4.6-fold higher neutralization titres than convalescent serum27,123”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [123]
In the citing paper
“In phase I trials of the two candidates, two 30 μg doses delivered 21 days apart induced high antibody and neutralizing titres and a robust CD4+ and CD8+ response with mild to moderate adverse events27,28,123,124.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [123]
In the citing paper
“with up to 75% showing moderate fever after a 30 μg boost vaccine [82].”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“Both local and systemic AE occurred dose-dependently, were mostly mild to moderate and more common after boost vaccination.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“events also peaked at day 2 after dosing and were resolved by day 7.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“despite the lower mRNA-doses used, AEs were reported more frequently with BNT162b1 as compared to mRNA-1273”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“Based on the reactogenicity to the 100 μg dose, no boost vaccination was performed at this dosage.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“fever was already reported after the first vaccination for all dose groups (8% for the 10 and 30 μg doses, 50% for the 100 μg dose)”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“Results of a phase 1/2 dose-escalation study (mRNA doses of 10–30-100 μg) revealed similar tolerability and safety.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationPersonalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Self-citationmRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Self-citationCOVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Self-citationCoronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020.
Stokes, E. K., Zambrano, L. D., Anderson, K. N., Marder, E. P., Raz, K. M., El Burai Felix, S., Tie, Y., & Fullerton, K. E. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6924e2 · Cited by 1,538
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
An Infectious cDNA Clone of SARS-CoV-2
Xie, X., Muruato, A., Lokugamage, K. G., Narayanan, K., Zhang, X., Zou, J., Liu, J., Schindewolf, C., Bopp, N. E., Aguilar, P. V., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.004 · Cited by 647
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,004
Inside the story about the research and development of COVID-19 vaccines
Patel, S. P., Patel, G. S., & Suthar, J. V. (2021) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2021.10.2.154 · Cited by 13
Lapić, I., Rogić, D., Šegulja, D., & Zaninović, L. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207572 · Cited by 13
Immunological Analysis of People in Northeast China after SARS-CoV-2 Inactivated Vaccine Injection
Fu, Y., Chen, F., Cui, L., Zhao, Y., Zhang, H., Fu, S., & Zhang, J. (2021) · Vaccines · doi:10.3390/vaccines9091028 · Cited by 13
A Digital Health System for Disease Analytics
Leung, C. K.-S., Fung, D. L. X., Mai, T. H. D., Souza, J., & Tran, N. D. T. (2021) · IEEE International Conference on Digital Health (ICDH) · doi:10.1109/icdh52753.2021.00019 · Cited by 15
A Case of Giant Cell Arteritis Presenting After COVID-19 Vaccination: Is it Just a Coincidence?
Greb, C., Aouhab, Z., Sisbarro, D., & Panah, E. (2022) · Cureus · doi:10.7759/cureus.21608 · Cited by 13
Antibody-Based Approaches to Target Pancreatic Tumours
Sorbara, M., Cordelier, P., & Béry, N. (2022) · Antibodies · doi:10.3390/antib11030047 · Cited by 15
Side Effects of COVID-19 Vaccines Among Diabetic Subjects and Healthy Individuals
Khan, F., Khan, M. T., Zaman, S., Mujtaba, S., Batool, A., Ghanghro, Z., Anwar, A., & Hashmi, A. A. (2023) · Cureus · doi:10.7759/cureus.36005 · Cited by 13
Liu, K., Lu, X., Shi, H., Xu, X., Kong, R., & Chang, S. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad414 · Cited by 13
Ftouh, M., Kalboussi, N., Abid, N., Sfar, S., Mignet, N., & Bahloul, B. (2021) · PPAR Research · doi:10.1155/2021/6741290 · Cited by 13
Bearth, A., Berthold, A., & Siegrist, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263351 · Cited by 13
RNA contact prediction by data efficient deep learning
Taubert, O., von der Lehr, F., Bazarova, A., Faber, C., Knechtges, P., Weiel, M., Debus, C., Coquelin, D., Basermann, A., Streit, A., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05244-9 · Cited by 11
Micco, P. D., Camporese, G., Cardillo, G., Lodigiani, C., Carannante, N., Annunziata, A., Fiorentino, G., Russo, V., & Imbalzano, E. (2021) · Medicina · doi:10.3390/medicina57100997 · Cited by 12
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 11
COVID-19 vaccination and liver disease
Ozaka, S., Kobayashi, T., Mizukami, K., & Murakami, K. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i48.6791 · Cited by 13
Qin, Q., Jiang, X., Huo, L., Qian, J., Yu, H., Zhu, H., Du, W., Cao, Y., Zhang, X., & Huang, Q. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02329-3 · Cited by 12
Yang, X., Liu, Y., Liu, Y., Yang, Q., Wu, X., Huang, X., Liu, H., Cai, W., & Ma, G. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1805315 · Cited by 12
An Inactivated Virus Candidate Vaccine to Prevent COVID-19
Mulligan, M. J. (2020) · JAMA · doi:10.1001/jama.2020.15539 · Cited by 12
Self-citationDoes COVID-19 Vaccination Warrant the Classical Principle “ofelein i mi vlaptin”?
Doulberis, M., Papaefthymiou, A., Kotronis, G., Gialamprinou, D., Soteriades, E. S., Kyriakopoulos, A. M., Chatzimichael, E., Kafafyllidou, K., Liatsos, C. N., Chatzistefanou, I., et al. (2021) · Medicina · doi:10.3390/medicina57030253 · Cited by 14
Ostadgavahi, A. T., Booth, R., Sisson, G. R., McMullen, N. M., Warhuus, M., Robertson, P., Miller, M., Allen, W. C., Sherif, M. E., Brownlie, R. M., et al. (2021) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.15368 · Cited by 12
Dash, R., & Mohapatra, S. (2021) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.21.02765-8 · Cited by 12
Speich, B., Chammartin, F., Smith, D. C., Stoeckle, M. P., Amico, P., Eichenberger, A. L., Hasse, B. K., Schuurmans, M. M., Müller, T., Tamm, M., et al. (2021) · Trials · doi:10.1186/s13063-021-05664-0 · Cited by 12
Daradkeh, M. K. (2021) · International Journal of Business Analytics · doi:10.4018/ijban.292056 · Cited by 16
Al‐Muhaiteeb, A., AlSahow, A., Alyousef, A., Alhelal, B. A., AlRajab, H., Bahbahani, Y., dewidar, N., & Fanous, G. N. M. (2022) · Hemodialysis International · doi:10.1111/hdi.13005 · Cited by 12
Seguridad de las vacunas contra la COVID-19
Chaparro-Mérida, N. A., Samper, D. M., & Lacato, A. O. F. (2021) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2021.384.9308 · Cited by 15
Why does COVID-19 continue to spread despite mass vaccination?
Zhang, S., Yang, Z., Chen, Z.-L., Yue, S., Zhang, S., & Tang, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.938108 · Cited by 12
Card, T. R., Nakafero, G., Grainge, M. J., Mallen, C. D., Nguyen‐Van‐Tam, J. S., Williams, H. C., & Abhishek, A. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002205 · Cited by 12
Rocha, V. P. C., Quadros, H. C., Fernandes, A. M. S., Gonçalves, L. P., Badaró, R. J. D. S., Soares, M. B. P., & Machado, B. A. S. (2023) · Viruses · doi:10.3390/v15071504 · Cited by 13
SARS-CoV-2 Spike Protein and Lung Vascular Cells
Suresh, S. J., & Suzuki, Y. (2020) · Journal of Respiration · doi:10.3390/jor1010004 · Cited by 12
A Review of the Progress of COVID-19 Vaccine Development
Ullah, S., Al-Sehemi, A. G., Klemeš, J. J., SAQIB, S., GONDAL, S. M. A., SAQIB, S., ARSHAD, A., Saqib, H., Mukhtar, A., IBRAHIM, M., et al. (2021) · Düzce Tıp Fakültesi Dergisi · doi:10.18678/dtfd.890089 · Cited by 12
Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform
Sa-nguanmoo, N., Namdee, K., Khongkow, M., Ruktanonchai, U., Zhao, Y., & Liang, X. (2021) · Nano Research · doi:10.1007/s12274-021-3832-y · Cited by 12
Shalash, A. O., Azuar, A., Madge, H. Y. R., Modhiran, N., Amarilla, A. A., Liang, B., Khromykh, A. A., Hussein, W. M., Chappell, K. J., Watterson, D., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040856 · Cited by 13
Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
Pinpathomrat, N., Intapiboon, P., Seepathomnarong, P., Ongarj, J., Sophonmanee, R., Hengprakop, J., Surasombatpattana, S., Uppanisakorn, S., Mahasirimongkol, S., Sawaengdee, W., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00475-z · Cited by 13
Meyers, E., Rop, L. D., Deschepper, E., Duysburgh, E., Burghgraeve, T. D., Ngoc, P. V., Digregorio, M., Delogne, S., Coen, A., Clercq, N. D., et al. (2022) · European Journal of General Practice · doi:10.1080/13814788.2022.2149732 · Cited by 12
COVID-19 Vaccination and Alcohol Consumption: Justification of Risks
Solopov, P. A. (2023) · Pathogens · doi:10.3390/pathogens12020163 · Cited by 12
Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign
Ferrari, D., Mangia, A., Spanò, S. M., Zaffarano, L., Viganò, M., Resta, C. D., Locatelli, M., Ciceri, F., & Vecchi, E. D. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0364 · Cited by 11
Fusco, F., Scognamiglio, G., Merola, A., Roma, A. S., Nicastro, C., Spatarella, M., D’Abbraccio, M., di Mauro, G., Atripaldi, U., Atripaldi, L., et al. (2021) · International Journal of Cardiology Congenital Heart Disease · doi:10.1016/j.ijcchd.2021.100266 · Cited by 11
Aleman, A., van Kesteren, M., Zajdman, A. K., Srivastava, K., Cognigni, C., Mischka, J., Chen, L., Upadhyaya, B., Serebryakova, K., Nardulli, J., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104886 · Cited by 10
Pacheco, T. J. A., da Silva, V. C. M., & de Souza, D. G. (2020) · Research Society and Development · doi:10.33448/rsd-v9i12.11123 · Cited by 11
Bhopal, S., Olabi, B., & Bhopal, R. S. (2020) · Public Health · doi:10.1016/j.puhe.2021.01.011 · Cited by 16
Srivastava, V., Niu, L., Phadke, K. S., Bellaire, B. H., & Cho, M. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637982 · Cited by 11
Tan, E., Frew, E., Cooper, J., Humphrey, J., Holden, M. T. G., Mand, A. R., Li, J., Anderson, S., Bi, M., Hatler, J. M., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11071190 · Cited by 11
Thrombosis formation after COVID-19 vaccination Immunological Aspects: Review article
Waggiallah, H. A. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.09.065 · Cited by 11
Diamanti, A. P., Rosado, M. M., Nicastri, E., Sesti, G., Pioli, C., & Laganà, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708848 · Cited by 11
BNT162b2 mRNA Vaccination Leads to Long-Term Protection from COVID-19 Disease
Rossi, C., Lanuti, P., Cicalini, I., Bellis, D. D., Pierdomenico, L., Boccio, P. D., Zucchelli, M., Natale, L., Sinjari, B., Catitti, G., et al. (2021) · Vaccines · doi:10.3390/vaccines9101164 · Cited by 11
A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization
Mattoo, S.-U.-S., & Myoung, J. (2021) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2111.11026 · Cited by 11
Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
Chatterjee, D., Tauzin, A., Laumaea, A., Gong, S. Y., Bo, Y., Guilbault, A., Goyette, G., Bourassa, C., Gendron‐Lepage, G., Medjahed, H., et al. (2022) · Viruses · doi:10.3390/v14010144 · Cited by 10
Al-Sa’ady, A. T., Abdulrasol, Z. A., Obaid, A. F., Al-Hindy, H. A.-A. M., & Al-Mumin, A. (2022) · Journal of emergency medicine, trauma & acute care · doi:10.5339/jemtac.2022.ismc.6 · Cited by 11
Non-capsular based immunization approaches to prevent Streptococcus pneumoniae infection
Silva, P. H., Vázquez, Y., Campusano, C., Retamal-Díaz, A. R., Lay, M. K., Muñoz, C. A., González, P. A., Kalergis, A. M., & Bueno, S. M. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.949469 · Cited by 12
Zhang, H., Jin, H., Yan, F., Song, Y., Dai, J., Jiao, C., Bai, Y., Sun, J., Liu, D., Wang, S., et al. (2022) · Virologica Sinica · doi:10.1016/j.virs.2022.12.006 · Cited by 11
Engineer RNA‐Protein Nanowires as Light‐Responsive Biomaterials
Younas, T., Liu, C., Struwe, W. B., Kukura, P., & He, L. (2023) · Small · doi:10.1002/smll.202206513 · Cited by 11
The Incidence of Graves’ Hyperthyroidism Before and After COVID-19 Messenger RNA Vaccination
Endo, M., Pinto, J., Roth, M. Y., Hoofnagle, A. N., Failor, R. A., & Tylee, T. S. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.05.005 · Cited by 11
Zhou, X., Song, S., Zhang, Y., & Hou, Z. (2023) · Journal of Medical Internet Research · doi:10.2196/49753 · Cited by 16
Bokharee, N., Khan, Y. H., Khokhar, A., Mallhi, T. H., Alotaibi, N. H., & Rasheed, M. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1902805 · Cited by 11
Wu, Y. Y., Walkover, M., & Zhang, W. (2021) · Social Science & Medicine · doi:10.1016/j.socscimed.2021.114285 · Cited by 11
Novel insights into the pathogenesis and treatment of NRAS mutant melanoma
Zhao, J. W., Galvez, C., Beckermann, K. E., Johnson, D. B., & Sosman, J. A. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1938545 · Cited by 11
RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement
Abdelzaher, H. M., Gabr, A. S., Saleh, B. M., Gawad, R. M. A., Nour, A. A., & Abdelnaser, A. (2021) · Vaccines · doi:10.3390/vaccines9111211 · Cited by 12
Yuniar, C. T., Pratiwi, B., Ihsan, A. F., Laksono, B. T., Risfayanti, I., Fathadina, A., Jeong, Y., & Kim, E. Y. (2022) · Vaccines · doi:10.3390/vaccines10020313 · Cited by 13
Optimal strategy for a dose-escalation vaccination against COVID-19 in refugee camps
Zheng, Q., Wang, X., Pan, Q., & Wang, L. (2022) · AIMS Mathematics · doi:10.3934/math.2022515 · Cited by 10
Nguyen, T. L., Lee, Y. H., & Kim, H. (2022) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-022-10382-5 · Cited by 11
Importance of the COVID-19 Vaccine Booster Dose in Protection and Immunity
Abdollahi, A., Afsharyzad, Y., Vaezi, A., & Meysamie, A. (2022) · Vaccines · doi:10.3390/vaccines10101708 · Cited by 12
Evolving spike-protein N -glycosylation in SARS-CoV-2 variantsPreprint
Baboo, S., Diedrich, J. K., Torres, J. L., Copps, J., Singh, B., Garrett, P. T., Ward, A. B., Paulson, J. C., & Yates, J. R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.08.539897 · Cited by 10
Vaccines on demand, part II: future reality
Geall, A. J., Kis, Z., & Ulmer, J. B. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2147501 · Cited by 10
Kumar, S., Jain, S., Wali, B., Zarnitsyna, V. I., Joshi, D., Ellis, M. L., Lai, L., Malik, A. A., McPherson, T., Godbole, S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu8067 · Cited by 12
Vaccine efficacy in mutant SARS-CoV-2 variants.
Kandikattu, H. K., Yadavalli, C. S., Venkateshaiah, S. U., & Mishra, A. (2021) · PubMed · doi:10.264195/ijcbp.isp · Cited by 10
Baral, P., Ahmed, T., Fernandez, P. A., Peters, M. A., Drouard, S. H. P., Muhoza, P., Mwinnyaa, G., Mwansambo, C. W., Nzelu, C. E., Tassembedo, M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288124 · Cited by 10
Batmunkh, T., Moore, K. A., Thomson, H., Altangerel, B., Amraa, O., Avaa, N., Batbayar, L., Batsukh, K., Bright, K., Burentogtokh, T., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100953 · Cited by 10
Holland, D. A., Acevedo‐Skrip, J., Barton, J. R., Thompson, R., Bowman, A. M., Dewar, E. A., Miller, D. V., Zhao, K., Swartz, A. R., & Loughney, J. W. (2024) · Vaccines · doi:10.3390/vaccines12080899 · Cited by 10
Next-generation COVID-19 vaccines: here come the proteins
Blakney, A. K., & McKay, P. F. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00258-0 · Cited by 10
Lizoňová, D., Frei, S., Balouch, M., Zadražil, A., & Štĕpánek, F. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00106 · Cited by 10
Kim, N., Shin, S., Minn, D., Park, S., An, D., Park, J. H., Roh, E. Y., Yoon, J. H., & Park, H. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac035 · Cited by 10
FACME multidisciplinary working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination (2021) · Neurología (English Edition) · doi:10.1016/j.nrleng.2021.05.001 · Cited by 10
Ali, M. D., Almadan, L. Z., Alghamdi, R. A., Alghamdi, A. S., Almarhoon, S. A., Hassan, Y. A., Ahmad, A., Ghosn, S. A., Banu, N., & Eltrafi, Z. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s374265 · Cited by 10
Recent advances in the vaccine development for the prophylaxis of SARS Covid-19
Kumar, V., Kumar, S., & Sharma, P. C. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109175 · Cited by 10
Success of nano-vaccines against COVID-19: a transformation in nanomedicine
Sarangi, M. K., Padhi, S. K., Rath, G., Nanda, S. S., & Yi, D. K. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2148659 · Cited by 11
Flu RNA Vaccine: A Game Changer?
Meurens, F. (2020) · Vaccines · doi:10.3390/vaccines8040760 · Cited by 9
Advanced microscopy technologies enable rapid response to SARS‐CoV ‐2 pandemic
Cortese, M., & Laketa, V. (2021) · Cellular Microbiology · doi:10.1111/cmi.13319 · Cited by 9
Xu, L., Doyle, J., Barbeau, D. J., Sage, V. L., Wells, A. H., Duprex, W. P., Shurin, M. R., Wheeler, S., & McElroy, A. K. (2021) · Pathogens · doi:10.3390/pathogens10060710 · Cited by 10
Clinical trial research on COVID-19 in Germany – a systematic analysis
Hirt, J., Rasadurai, A., Briel, M., Düblin, P., Janiaud, P., & Hemkens, L. G. (2021) · F1000Research · doi:10.12688/f1000research.55541.1 · Cited by 8
A Trans-Governmental Collaboration to Independently Evaluate SARS-CoV-2 Serology Assays
Pinto, L. A., Shawar, R. M., O’Leary, B., Kemp, T. J., Cherry, J. D., Thornburg, N. J., Miller, C. N., Gallagher, P. S., Stenzel, T. T., Schuck, B. W., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01564-21 · Cited by 10
Chen, P., Chuang, P.-N., Chiang, C., Chang, H., Lu, C., & Huang, K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262660 · Cited by 10
Tien, N., Chang, Y.-C., Chen, P., Lin, H., Chang, S., Lan, J., Hsueh, P., Chang, C., & Chen, D. (2022) · Biomedicines · doi:10.3390/biomedicines10040911 · Cited by 10
Lau, O., & Vadlamudi, N. K. (2021) · Value in Health · doi:10.1016/j.jval.2021.09.003 · Cited by 10
A rational strategy to support approved COVID-19 vaccines prioritization
Burgos-Salcedo, J. D. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1922060 · Cited by 9
Alishetty, S., Carrasco, M. J., Alameh, M., Paige, M. A., Said, H., Wright, L., Narayanan, A., Alem, F., Hernandez, K. R., Gillevet, P. M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-798453/v1 · Cited by 10
Enhancement of synthetic mRNA translation efficiency through engineered poly(A) tails
Liu, Y., Nie, H., Sun, R., Wang, J., & Lu, F. (2021) · doi:10.1101/2021.08.30.458298 · Cited by 11
Chen, G., Qiu, Y., Wu, K., Wu, Y., Wang, Y., Zou, Y.-Y., Peng, C., Zhao, J., Su, C., Ma, J.-H., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2285089 · Cited by 9
Molecular basis of Ad5-nCoV vaccine-induced immunogenicity
Dong, D., Song, Y., Wu, S., Wang, B., Peng, C., Zhang, W., Kong, W., Zhang, Z., Song, J., Hou, L., et al. (2025) · Structure · doi:10.1016/j.str.2025.02.009 · Cited by 8
Akula, V. R., Bhate, A. S., Gillurkar, C. S., Kushwaha, J. S., Singh, A. P., Singh, C., Pandey, A. K., K, S. K., Rai, S. K., Vadrevu, K. M., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00818-6 · Cited by 11
SPICA Force Field for Nucleic Acids and Its Application to Lipid Nanoparticles
Singh, A. P., Tanaka, H., Miyazaki, Y., & Shinoda, W. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c01729 · Cited by 8
Ikrar, T., Muchsin, W., & Sophian, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115019 · Cited by 10
Blazquez‐Navarro, A., Safi, L., Meister, T. L., Thieme, C. J., Kaliszczyk, S., Paniskaki, K., Stockhausen, M., Hörstrup, J. H., Cinkilic, O., Flitsch-Kiefner, L., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.07.006 · Cited by 9
Possibility of new shielding device for upper gastrointestinal endoscopy
Kikuchi, D., Ariyoshi, D., Suzuki, Y., Ochiai, Y., Odagiri, H., Hayasaka, J., Tanaka, M., Morishima, T., Kimura, K., Ezawa, H., et al. (2021) · Endoscopy International Open · doi:10.1055/a-1523-8959 · Cited by 9
Development of synthetic antigen vaccines for COVID-19
Invenção, M. D. C. V., Melo, A. R. D. S., de Macêdo, L. S., Neves, T. S. P. D. C., de Melo, C. M. L., Cordeiro, M. N., Batista, M. V. D. A., & de Freitas, A. C. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1974288 · Cited by 10
COVID-19 Vaccination-Induced Myopericarditis: An Imager’s Perspective
Bews, H. J., Bryson, A., Bortoluzzi, T., Tam, J. W., & Jassal, D. S. (2022) · CJC Open · doi:10.1016/j.cjco.2022.01.007 · Cited by 9
Yang, W.-X., Zhang, D.-X., Li, Z., & Zhang, K. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.031 · Cited by 9
Calcoen, B., Callewaert, N., Vandenbulcke, A., Kerstens, W., Imbrechts, M., Vercruysse, T., Dallmeier, K., Weyenbergh, J. V., Maes, P., Bossuyt, X., et al. (2022) · Viruses · doi:10.3390/v14061257 · Cited by 8
Emerging trends of research on mRNA vaccines: A co-citation analysis
Chen, J., Zhang, T., Lu, Y. Z., Yang, X., & Ouyang, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2110409 · Cited by 10
Enayatrad, M., Mahdavi, S., Aliyari, R., Negah, S. S., Nili, S., Fereidouni, M., Shahrbabaki, P. M., Ansari‐Moghaddam, A., Heidarzadeh, A., Shahraki‐Sanavi, F., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08103-4 · Cited by 9
Donhauser, L. V., de Oliveira, J. V., Schick, C., Manlik, W., Stýblová, S., Lutzenberger, S., Aigner, M., Philipp, P., Robert, S., Gandorfer, B., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007387 · Cited by 9
Next Generation Influenza Vaccines: Looking into the Crystal Ball
Guzmán, C. A. (2020) · Vaccines · doi:10.3390/vaccines8030464 · Cited by 10
Metadata
- Authors
- Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P.-Y., Türeci, Ӧ., Tompkins, K. R., Walsh, E. E., Frenck, R., Falsey, A. R., Dormitzer, P. R., Gruber, W. C., Şahin, U., & Jansen, K. U.
- Affiliations
- NYU Langone Health (US)
- University of Maryland, Baltimore (US)
- Pfizer (United Kingdom) (GB)
- Pfizer (United States) (US)
- The University of Texas Medical Branch at Galveston (US)
- Rochester General Hospital (US)
- Cincinnati Children's Hospital Medical Center (US)
- BioNTech (Germany) (DE)
- Corresponding author
- Absalon, Judith
- ORCID
- Mulligan, Mark J.
- Lyke, Kirsten E.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Neuzil, Kathleen
- Raabe, Vanessa
- Swanson, Kena A.
- Li, Ping
- Cooper, David
- Fontes-Garfias, Camila
- Shi, Pei-Yong
- Tompkins, Kristin R.
- Walsh, Edward E.
- Frenck, Robert
- Falsey, Ann R.
- Dormitzer, Philip R.
- Gruber, William C.
- Şahin, Uğur
- Jansen, Kathrin U.
- Venue
- Nature
- Publisher
- openRxiv
- Published
- 2020-07-01
- Volume
- 586
- Issue
- 7830
- Pages
- 589-593
- ISSN
- 0028-0836 (ISSN-L)
- OpenAlex
- W3048620154
- Cited by
- 1,569
- References
- 24
- Citations by year
- 2026: 47 · 2025: 92 · 2024: 111 · 2023: 183 · 2022: 355 · 2021: 623 · 2020: 152
- FWCI
- 43.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Pfizer
- Cincinnati Children's Hospital Medical Center
- University of Rochester
- Georgia Clinical and Translational Science Alliance
- National Institutes of Health (UL1TR001445)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, dose escalation, vaccine safety, vaccine immunogenicity, neutralizing antibodies, reactogenicity, healthy adults
- MeSH terms
- COVID-19, COVID-19 Vaccines, COVID-19 Serotherapy, Adult, Antibodies, Viral, Female, Humans, Immunoglobulin G, Immunization, Passive, Male, Middle Aged, Pneumonia, Viral, Time Factors, Viral Vaccines, Coronavirus Infections, Young Adult, Antibodies, Neutralizing, Pandemics, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
